Supply Chain

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.

How Will Upcoming Chinese Tariffs Affect Chemical Distribution? with Ben Sawicki & Matt Francoeur of The Chemical Company

Coming in response to China’s Made In China 2025 initiative, which pushes to make China a competitor in advanced manufacturing, a flurry of tariffs is leaving many U.S. businesses unsure of what the future holds for Chinese trade relationships. The main tariffs going into affect in the next few months include Section 232 tariffs,…